Mainstreaming ME Research BRMEC6

Invest in ME Research Biomedical Research Colloquiums

The Invest in ME Research Biomedical Research into ME Colloquiums are research meetings organised by the charity to encourage biomedical research into ME and international collaboration amongst researchers.
This is one of the main objectives of the charity. Invest in ME Research began arranging biomedical research conferences in our first year and have continued them ever since - mostly funded by the charity but with help from some wonderful supporters and some good friends.

The Invest in ME International Biomedical Research into ME Colloquiums began in 2011 as a way of bringing together researchers from around the world in a round-table discussion of ME research and ideas.

Over the years this has broadened into sharing of experiences, data and plans for future research.
A culmination of much of this effort has been the formation of The European ME Research Group (EMERG) which met in October 2015 in London to set up a strategy of European collaboration in ME research.

We now have a basis for creating a strategy of high-quality international biomedical research - something which has been lacking in the past.
This will hold great promise of finding funding opportunities and raising awareness of biomedical research into ME.

Our aim with the annual CPD-accredited research colloquiums has also been to introduce new researchers into the field of ME research, to gain new insights into the disease and enhance the strategy of research we are building.

The colloquiums have spawned a number of positive initiatives over the years.
Almost 70 researchers from thirteen countries attended the BRMEC5 Colloquium in 2015.

We will continue to bring in new researchers from outside the ME field to enhance the knowledge and ideas - something the charity has proudly been doing from its beginning.


Biomedical Research into ME Colloquium 6 - 1st - 2nd June 2016


IIMER BRMEC6 Research Meeting London, 2016

1st - 2nd June 2016

The Biomedical Research into ME Colloquium 6 (BRMEC6) takes place in London over two days from 1st - 2nd June 2016.

This will be the sixth Invest in ME research Colloquium and we hope to emulate last year's successful meeting which brought together top researchers from thirteen countries to discuss research, strategies and future planning.

The fifth colloquium built on past years and has now evolved into a major international event, with CPD accreditation, and involving the most experienced researchers in areas such as immunology, virology, neurology and bioinformatics.

Chairing and participating in the meeting will be the Invest in ME Research Advisory Board and the newly formed European ME Research Group (EMERG).

We again have most of the main biomedical research initiatives now occurring throughout the world represented at the meeting.

Participation in BRMEC* Events

The research colloquium is a workshop environment for active and potential ME researchers and is by invitation only. However, the charity welcomes applications from researchers interested in increasing the knowledge and research into ME.

If you are a researcher and are interested in attending the BRMEC* Colloquiums then please use our contact form to discuss this -


BRMEC6 - Day 1
Welcome to the 6th Invest in ME International Biomedical Research into ME Colloquium Dr Ian Gibson/ Professor Jonathan Edwards
tbc
Diagnosis (clinical) – Patient Stratification (including the following)
Clinical signs/symptoms of ME
Diagnostics and Patient Stratification for Rresearch
Protocols and Patient Databases for ME
Big Data Approach: Severely Ill ME Cohort
Chaired Discussion - Criteria to Use for ME/CFS Diagnosis
Sample Standardisation SOPs for Research (including the following)
Biobank Samples and Protocols for UK/Europe
Analysis Protocols for ME
Chaired discussion Sample Standardisation SOPs for Research
Biomarkers: 1 Data (including the following)
Keynote Speech: Longitudinal Immunological & Virological Study for ME/CFS Biomarker Discovery
Chaired discussion/workshop with participants
Biomarkers: 2 Imaging (including the following)
Immune-Brain Communication and Relationship to Inflammation and Cohort Selection Challenges
Neuroimaging in Clinical Practice in ME
Chaired Discussion Neuroimaging in ME Research
Biomarkers: 3 Mitochondria (including the following)
Keynote Speech: Understanding and Preventing Mitochondrial Oxidative Damage
Mitochondria in ME/CFS
Chaired discussion/workshop with participants
Adjourn

BRMEC6 - Day 2
A Strategy of ME/CFS Research - Objectives of DAY 2 Dr Ian Gibson/ Professor Jonathan Edwards
Biomarkers: 4 Antibodies (including the following)
Autoantibodies in ME/CFS
Antibodies to small DNA viruses
B cell biology and ME
Novel form of RnaseL
Chaired discussion Antibodies in ME/CFS
Biomarkers: 5 Big Data Updates (including the following)
Big Data Approach for ME/CFS at Columbia University
Big Data Update from Stanford
Recent discoveries from NCNED data set: Gene expression & Receptor id
Chaired discussion - Challenges of Big Data Strategies
Biomarkers: 6 Phenotypes (including the following)
Glucocorticoid Resistance in ME
Exercise Data, Orthostatic Tachycardia and Proteomics in ME
Virome and Gut Microbiota in ME
Chaired discussion/workshop with participants
Systems Biology (including the following)
A Systems Biology approach
Chaired discussion participants
Novel Treatments (including the following)
Novel Treatments - Immunoadsorption
Medical Education (including the following)
Medical Education - BMJ Update
Chaired discussion with participants
SUMMARY of BRMEC6 - Objectives Status
Adjourn

Biomedical Research into ME Colloquium 5 - 27-28th May 2015


BRMEC5 IiME Research Meeting London, 2015

The Biomedical Research into ME Colloquium 5 (BRMEC5) took place over two days from 27th-28th May 2015.

This was the fifth Invest in ME Research Colloquium and over sixty researchers from thirteen countries round the world convened in London to discuss research, strategies and future planning.

The fifth colloquium built on past years and has now evolved into a major international event, with CPD accreditation, and involving the most experienced researchers in areas such as immunology, virology, neurology and bioinformatics.

Chairing the meeting was Dr Ian Gibson and Professor Jonathan Edwards - along with the Invest in ME Research Advisory Board.

The research meeting was by invitation only but the charity made available places for researchers and some students who would add to the meeting or who were interested collaborating with our increasing group of international researchers in performing biomedical research into ME.

We had representatives from most of the main biomedical research initiatives now occurring throughout the world represented at the meeting.

BRMEC5 - Day 1
Welcome to the 5th Invest in ME International Biomedical Research into ME Colloquium Dr Ian Gibson/ Professor Jonathan Edwards
Foundations for Research
Epidemiology: Incidence/Prevalence in UK Dr Luis Nacul, London School of Hygiene and Tropical Medicine, UK
Diagnostics/patient selection for research -
Experience from clinic/Characteristics of patients – from new to severely ill
Dr Amolak Bansal, Epson and St.Helier NHS University Hospital, UK
IOM Implications Dr Dan Peterson, Simmaron Research, USA
Discussions
Chaired discussion with participants
Immunology 1: Gut Microbiota - Session Lead Professor Simon Carding (IFR)
USA Columbia Microbiome study Prof Mady Hornig, Columbia Univ, USA
The Cornell Microbiome Study Prof Maureen Hanson Cornell Uni,USA
Discussions
Chaired discussion with participants
Immunology 2:
Immunological and metabolic markers Prof Mady Hornig Columbia Univ, USA
B cell biology Dr Jo Cambridge UCL, UK
Immunological markers in a Spanish patient cohort Dr Julian Blanco, Irsi Caixa, Spain
Lymphocyte markers of fatigue in CFS/ME & breast cancer patients Dr Clive Carter, Leeds Teaching Hospitals NHS Trust, UK
Cytokine and Chemokine Profiles of ME/CFS Patients Dr Amir Landi, University of Alberta, Canada
Discussions
Chaired discussion with participants
Virology
Enteroviral Research into ME/CFS Dr John Chia, UCLA, USA
EBV and ME/CFS Prof Carmen Scheibenbogen Charite, Berlin, DE
Discussions Chaired discussion with participants
Summary of first day Dr Ian Gibson, UEA, UK
Prof Jonathan Edwards, UCL, UK
Adjourn

BRMEC5 - Day 2
Welcome - Overview/summary of previous day Objectives of DAY 2 Dr Ian Gibson, UEA, UK Prof Jonathan Edwards, UCL, UK
Neurology: Lead Angela Vincent (Oxford Univ.)
Keynote Speech:
Imaging Inflammation and Its Role in Neurodegeneration
Professor David Brooks, Imperial College London, UK
Immune-Brain Communication and Relationship to Inflammation Dr Neil Harrison Sussex Uni, UK
FMRI and ME/CFS Prof James Baraniuk Georgetown University, USA
Discussions
Chaired discussion with participants
Biomarkers
Immunological markers in ME/CFS Professor Sonya Marshall-Gradisnik
Professor Don Staines Griffiths University, Australia Australia
Vision and ME/CFS Dr Claire Hutchinson Leicester Uni., UK
CSF Proteomics in a Swedish ME/CFS patient cohort Prof Jonas Bergquist Uppsala Uni, Sweden Sweden
Glucocorticoid receptors and ME/CFS Dr Amolak Bansal, Epsom and St Helier NHS University Hospital, Surrey, UK
Molecular markers before/after exercise Prof Betsy Keller, Cornell Uni, USA
Discussions
Chaired discussion with participants
Clinical trials
Trial design, good practice Prof Jonathan Edwards, UCL, UK
Norwegian rituximab research/trials Prof Olav Mella/ Dr Oystein Fluge Haukeland Uni.,Norway
Discussions
Chaired discussion with participants
Additional Topics
Funding tbc
Discussions
Chaired discussion with participants
Adjourn



Some of the Participants at BRMEC5


Biomedical Research into ME Colloquium 4 - 2014

IiME Research Meeting London, 2014

Invest in ME made the commitment to continue to organise and host the Biomedical Research into ME Colloquium 4 collaborative meeting - this time in May 2014. This international researchers meeting followed on from the successful BRMEC2 and BRMEC3 meetings of 2012 and 2013.

The BRMEC4 Colloquium was intended to harness the potential of international collaboration with an objective of extending research cooperation and help drive new initiatives with biomedical research into ME.

The research meeting was in London and preceded the IIMEC9 annual international biomedical research conference on 30th May 2014.

Almost 50 researchers from nine countries attended the colloquium and a number of new initiatives were created which will benefit biomedical research into ME.

Welcome to London and BRMEC4 2014

Dear Participants,

Welcome to the Invest in ME Biomedical Research for ME Colloquium Meeting (BRMEC4) on 29th May 2014. Thank you again for participating in this exciting and innovative meeting which builds on the foundations made in previous years through meetings organised by the dedication and commitment of Invest in ME and its supporters.

Promising developments have been initiated in recent years which have created important possibilities for changing the way that Myalgic Encephalomyelitis (ME, known also as or ME/CFS or Chronic Fatigue Syndrome (CFS)) is researched and the way that patients are treated. High-quality research by an impressive group of researchers and physicians, with an emphasis on international collaboration - these are the aims of Invest in ME and it is our intention to continue to facilitate this and encourage new scientific research endeavours to understand the pathogenesis of ME.

This will be our fourth international ME research colloquium in London, taking place prior to our annual IiME international conference, and we look forward to enabling a unique contribution to understanding ME and suggest future research. For those who can use CPD points then this meeting has been awarded 6 CPD points by the Royal Colleges.

Co-Chairs of the meeting will be Dr Ian Gibson, former Dean of Biology at UEA, and Emeritus Professor of Connective Tissue Medicine Jonathan Edwards, University College London.

We look forward to meeting up in London.

Warm regards

Kathleen McCall Chairman Invest in ME

Invest in ME BRMEC4
Welcome and introductions Co-Chairs: Dr. Ian Gibson Prof.Jonathan Edwards UCL
Pathogen Discovery and Pathogenesis - CFI Dr. Mady Hornig, Columbia Univ, USA
Infection-induced autoimmunity in ME Prof. Jonas Blomberg, Uppsala Univ, Sweden
Microbiome of ME/CFS patients Prof. Maureen Hanson, Cornell Univ.,USA
OMI research Update Dr Andreas Kogelnik, OMI, USA
Chaired Discussions Prof. Jonathan Edwards/Dr.Ian Gibson
Antibodies in Neurological Diseases Prof. Angela Vincent, Oxford Univ.
Rituximab multi-centre clinical trial Prof.Olav Mella/Dr. Oystein Fluge, Bergen, Norway
Rituximab UK clinical
- Preliminary B-cell study
Dr. Jo Cambridge, UCL, UK
EBV and ME Prof. Carmen Scheibenbogen, Charite, Berlin
Chaired Discussions Prof. Jonathan Edwards/Dr.Ian Gibson
Update on ANS studies Prof. Julia Newton, Newcastle, UK
Brain imaging and ME Prof. James Baraniuk Georgetown Univ., USA
NK-, B- and T-cell phenotypes and function in patients suffering from ME Prof. Sonya Marshall-Gradisnik, Griifiths Univ.,Australia
ME Biobank Dr. Eliana Lacerda/Dr Luis Nacul, LSHTM
Chaired Discussions Prof. Jonathan Edwards/Dr.Ian Gibson
Ways to Continue Collaboration and Discovery Funding Possibilities - IiME Proposal Plenary: Prof. Jonathan Edwards/Dr.Ian Gibson
Closing Summary and Future Directions Prof. Jonathan Edwards/Dr.Ian Gibson Briefing to Invest in ME Conference

A report of BRMEC4/IIMEC9


Biomedical Research into ME Colloquium 3 - 2013

IiME Research Meeting London, 2013

In May 2013 the Biomedical Research into ME Collaborative meeting was held in London with 40 researchers from 9 countries attending, prior to the IIMEC8 Invest in ME International ME Conference 2013 - http://bit.ly/ZK7eoC To raise awareness of ME, and promote collaboration, innovation and foundations for a clearer strategy of biomedical research into ME, Invest in ME and the Alison Hunter Memorial Foundation of Australia continue the collaboration which has been a feature for several years, and which established the Clinical Autoimmunity Working Group which met in London in May 2012.

To achieve continued progress in understanding and treating this disease we must establish collaborations between biomedical researchers who can agree a clear strategy of biomedical research. Therefore, to attempt to increase collaboration and awareness and to encourage new researchers to the field we are arranging a research meeting which brings together major researchers in order to crowd source ideas on ME research - a Biomedical Research into ME Collaborative meeting. Representatives from seven countries attended.

Since its inception Invest in ME have campaigned for biomedical research into ME. IiME began arranging our biomedical research conferences in our first year and have continued them ever since - mostly funded by the charity but with help from some wonderful supporters and some good friends.

At our IIMEC8 conference we focus on ME now becoming a mainstream research area. We have representatives from most of the main biomedical research initiatives now occurring throughout the world.

Welcome to London and BRMEC3 2013

Dear Friends,

It is an honour to welcome you to London and the Biomedical Research into ME Collaborative meeting. This meeting has been made possible through the continued commitment to biomedical research being made by UK charity Invest in ME and their supporters.

The objectives of the meeting are:

1. To present the status of the latest initiatives occurring in biomedical research into ME

2. To discuss and explore the possibilities for collaboration and for funding for biomedical research into ME

3. To generate new ideas regarding research into ME and assess research strategies for ME research

4. Review evidence for immunological derangement in ME

5. Review experiences and expertise from other research areas in order to assist ME research

6. To discuss opportunities for extending clinical trials in multiple centres and possibly internationally

7. To plan future events

We hope that the meeting will initiate new collaborations and generate new ideas for biomedical research into ME and help researchers support each other in the future.

The extraordinary skill and experience which can be harnessed by meetings such as last year’s Clinical Autoimmunity Working Group meeting in London and this year’s BRMEC meeting, as well as the possibilities to progress further understanding of the disease by “crowdsourcing” experience and ideas, promises to enable a unique contribution to understanding ME and suggest future research directions and perhaps treatments.

Chairing the meeting will be Dr Ian Gibson, former Dean of Biology at UEA and Professor Hugh Perry of Southampton University Chair of the Medical Research Council Neurosciences and Mental Health Board.

Invest in ME is keen and willing to support further collaborative efforts in biomedical research into ME and welcome the opportunity to continue these joint efforts,

Warm regards

Kathleen McCall Chairman Invest in ME

Invest in ME BRMEC3
Welcome and introductions (Chairs: Dr Ian Gibson/Professor Hugh Perry)
Pathogen Discovery and Pathogenesis = CFI (Professor Mady Hornig)
Retroviruses and ME (Professor Greg Towers)
Pathogen Discovery (Professor Jonas Blomberg)
Gut Microbiota and ME (Professor Simon Carding)
Chaired Discussions (Dr Ian Gibson/Professor Hugh Perry)
Experience of Rituximab in ME/CFS and present a case for extending clinical trials
as per Norwegian protocols or other parallel trials
(Dr Oystein Fluge/ Professor Olav Mella)
Rituximab in autoimmune diseases (Dr Jo Cambridge)
Update on immunological derangement that may dovetail with the Fluge et al findings. (Dr Don Staines)
Screening NK-, B- and T-cell phenotype and function in patients suffering from ME (Dr Julià Blanco)
Chaired Discussions (Dr Ian Gibson/Professor Hugh Perry)
ANS studies (Professor Julia Newton)
FDA Meeting outcome /Treatment with Vistide (Dr Dan Peterson)
OMI MERIT Strategy (Dr Andy Kogelnik)
Chaired Discussions (Dr Ian Gibson/Professor Hugh Perry)
Funding Possibilities
Ways to Continue Collaboration and Discovery
Chaired Discussions (Dr Ian Gibson/Professor Hugh Perry)
Closing Summary and future directions (Ian Gibson/Hugh Perry/IIME)

Biomedical Research into ME Colloquium 2 - 2012

IiME Research Meeting London, 2012

To raise awareness of ME, and promote collaboration, innovation and foundations for a clearer strategy of biomedical research into ME, Invest in ME has joined with the Alison Hunter Memorial Foundation of Australia - in cooperation with Bond University and University of East Anglia - to establish a Clinical Autoimmunity Working Group which met in London on 30-31st May 2012.

Kathleen McCall
Chairman Invest in ME

There is an urgent need for a coordinated strategy of biomedical research into myalgic encephalomyelitis (ME).
Good quality collaborative research efforts lead to understanding of the disease and better patient care and education of health care professionals.
The approach to treating ME must reflect the latest biomedical research evidence and ME needs to be accepted as a mainstream disease requiring major attention from the medical profession and research institutions.
Patients need access to knowledgeable ME consultants who can make correct diagnoses using proper guidelines and need to understand the disease in its all phases.
Invest in ME is a UK charity established in 2006 by ME patients and parents of children with ME.
The charity was set up with the objectives of making a change in how ME is perceived and treated in the media, by health departments and by healthcare professionals.
Our efforts are focused on setting up a UK Centre of Excellence which will provide proper examinations and diagnosis for ME patients and initiate a coordinated strategy of biomedical research into ME in order to find treatment(s) and cure(s).

Christine Hunter AM
Alison Hunter Memorial Foundation

People with ME face enormous obstacles to access health care. Among the impediments over past decades has been research which has shifted emphasis to fatigue and fatigue states with scant regard for the myriad yet distinguishing neurological, autonomic, and gastrointestinal features of ME. Semantics and biased attributions continue to deny the severely ill, both child and adult, the right to care which addresses their acute and chronic medical needs without fear. The Alison Hunter Memorial Foundation was established in 1998 through the initiative of the Public Interest Advocacy Centre, Sydney. The Foundation has a primary interest in the medical, legal and social needs of people with ME and the clinical documentation of severity. The Foundation supports biomedical research.

INTERNATIONAL SCIENTISTS EXPLORE AUTOIMMUNITY IN MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME

Wednesday 30th Thursday 31 May 2012, LONDON, UNITED KINGDOM


Medical and scientific experts from around the world convened in London on 30 and 31 May to discuss recent scientific developments in understanding myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Co-Chair of the clinical autoimmunity working group for ME/CFS, public health physician Dr Don Staines stated ‘The recent discovery from researchers in Norway that an anti- CD20 B cell- depleting drug had a marked benefit in the treatment of ME/CFS has sent a clear message to scientists and medical practitioners around the world that this disease may have an autoimmune origin'.

While the clinicians who made the discovery, Dr Oystein Fluge and Dr Olav Mella and co-workers remain guarded in drawing unwarranted conclusions from the study published in PLoS late last year, further studies are now being planned in the hope of extending the study to a number of clinical sites and to increase the number of patients in the studies.

Dr Staines said �The findings of Drs Fluge and Mella and their co-workers are consistent with theories previously published that ME/CFS may be an autoimmune disease. Despite compelling evidence that this disease is linked epidemiologically to infection and the disorder possibly being a post-infection disturbance of the immune system, little funding has gone into studies of autoimmunity. This is clearly a multi-system illness which has been badly managed in terms of the research agenda.'

Experts who will attend the meeting include Professor Noel Rose, Director of Autoimmune Disease Research at Johns Hopkins Hospital (USA), Professor Stephen Miller (USA), Dr Mario Delgado (Spain) and Professor Hugh Perry, the chairman of the UK Medical Research Council Neurosciences and Mental Health Board. Immunological discoveries which may serve to act as biomarkers for ME/CFS will be presented by Dr Sonya Marshall-Gradisnik, Bond University, Australia.

Alison Hunter Memorial Foundation chunter@ahmf.org +61 2 99586285 Invest in ME info@investinme.org 07759 349743

WELCOME ADDRESS: DAME BRIDGET OGILVIE, AC DBE FRS
CONVENORS

BOND UNIVERSITY, Population Health and Neuroimmunology Research Unit, Faculty of Health Sciences and Medicine, Gold Coast Australia UNIVERSITY OF EAST ANGLIA, Biomedical Research Centre, Faculty of Science, Norwich, United Kingdom GRIFFITH UNIVERSITY, School of Medical Science, Griffith Health Institute, Gold Coast, Australia
ALISON HUNTER MEMORIAL FOUNDATION, AUSTRALIA
INVEST IN ME, UNITED KINGDOM

PARTICIPANTS
  • Dr Amolak Bansal MD
  • Dr. James N Baraniuk MD
  • Dr Monica Carson PhD
  • Professor Simon Carding PhD
  • Dr Abhijit Chaudhuri MD PhD
  • Dr Mario Delgado PhD
  • Dr Oystein Fluge MD PhD
  • Dr Ian Gibson PhD
  • Dr Konstance Knox PhD
  • Dr Andreas Kogelnik MD PhD
  • Dr Richard Kwiatek MBBS FRACP
  • Professor Stephen D. Miller PhD
  • Dr Sonya Marshall-Gradisnik PhD
  • Professor Olav Mella MD PhD
  • Dame Bridget Ogilvie AC, DBE, FRS
  • Professor Hugh Perry PhD
  • Dr Daniel Peterson MD
  • Professor Noel Rose MD PhD
  • Dr Katherine Rowe MD MBBS FRACP MPH DipEd
  • Dr Rosamund Vallings MD
  • Professor Tom Wileman PhD
BRMEC2 - CAWG Day 1
Welcome address Dame Bridget Ogilvie AC DBE FRS
Overview of criteria required to support an autoimmune basis to ME/CFS Noel Rose MD PhD Professor Johns Hopkins Bloomberg School of Public Health Director Center for Autoimmune Disease Research Baltimore USA
Review of experience of Rituximab in ME/CFS Oystein Fluge MD PhD University of Bergen Institute of Medicine, Section for Oncology Haukeland
Regulation of EAE using antigen-specific tolerance and B cell targeting - Stephen Miller PhD Professor Northwestern University Feinberg School of Medicine Judy Guggenheim Research Professor of Microbiology-Immunology Chicago USA
Potential for pathogenicity of autoimmunity to vasoactive neuropeptides and their receptors Mario Delgado PhD Head of Department of Immunology and Cell Biology The Institute of Parasitology and Biomedicine Granada Spain
Exploring autoimmune pathomechanisms in ME/CFS Sonya Marshall Gradisnik PhD Associate Professor Bond University Faculty of Health Sciences and Medicine Gold Coast Australia
Do symptoms match putative autoimmune targets in ME? Don Staines MBBS MPH Public Health Medical Officer Gold Coast Public Health Unit Associate Professor (Adjunct) Bond University, Griffith University, Queensland Australia
Symptomatology of the clinical spectrum of ME/CFS Daniel Peterson MD Adjunct Professor Bond University Gold Coast CEO Simmaron Research Foundation for Chronic Fatigue Syndrome Incline Village USA
Plenary session Chair: Ian Gibson PhD
BRMEC2 - CAWG Day 2
Overview/summary of previous day Objectives of DAY 2 Tom Wileman PhD Don Staines MBBS MPH
Developments in neuropathology Hugh Perry PhD Professor University of Southampton Experimental Neuropathology Centre for Biological Sciences Southampton UK
MRI evidence: Microvascular changes in CNS Richard Kwiatek MBBS FRACP Lyell McEwin Hospital Senior Visiting Medical Specialist in Rheumatology Adelaide Australia
Genetics and informatics Andy Kogelnik MD PhD Director Open Medicine Institute Mountain View CA USA
Plenary session Chair: Ian Gibson PhD
Lessons from neuropathology of ME/CFS Abhijit Chaudhuri DM MD PhD FACP FRCP Glasg FRCP Lond Senior Consultant Neurologist Queen's Hospital Romford Essex Centre for Neurological Sciences UK
Plenary Session: Open discussion: Collaboration strategies which might target research agencies such as NIH (US), NHMRC (Aus), MRC (UK). Consider developing an overarching strategic approach Chair: Ian Gibson PhD
Summary and future directions Chair: Ian Gibson PhD
Acknowledgements and Close Invest in ME / Alison Hunter Memorial Foundation

Biomedical Research into ME Colloquium 1 - 2011

IiME Research Meeting London, 2011

In May 2011, during the IIMEC6 conference weekend events, the charity included a new IiME idea - the 'Corridor Conference' - with clinicians and researchers discussing ways to collaborate, discuss issues and generally to progress knowledge and opportunities for research.

Thus was born the Invest in ME Biomedical Research into ME Colloquium - an event where researchers, and clinicians, from around the world, could cooperate, share experiences and ideas and form future collaborations which would help overcome the lack of funding being given to biomedical research into ME by those bodies responsible for granting funding.
In this way Invest in ME sought to facilitate the type of high-quality research which we feel is the foundation for finding treatments and cures for ME

from Ros Vallings' IIMEC8 conference report

"...top researchers who were presenting at the conference, and a few others who were attending, were gathered together to discuss their current research and to look at opportunities for ongoing collaboration. This was a 'closed' meeting, but I was lucky to be able to go along as an observer. Much of the research discussed was embargoed for any mention here, as is still awaiting publication. However we were fortunate to have a fascinating 30 minute talk from Professor Burnstock on his theories and research on purine signalling. This talk was repeated the following day at the conference (see below). I was glad to be able to hear it twice as it was complex biochemically. This could have much relevance in ME/CFS. All the researchers were keen to have ongoing contact with a view to collaboration."


The Invest in ME International ME Research Conferences

More details of the Invest in ME conferences can be found on the current IIMEC* conference page.


Invest in ME Research Projects

Possibly the two most important research projects for ME in the UK
Both initiated and funded by Invest in ME Research and our supporters

CONTACT US

Contact Us

Contact Us

If you have any questions regarding the conference then please contact us by email and we will get back to you as soon as possible. Thank you for your interest in the International ME Conference.


Contact Address

  • Address: Invest in ME PO Box 561 Eastleigh SO50 0GQ Hampshire UK
  • Phone: 07759 349743
  • Fax: 02380 000040
  • Email: meconference@investinme.org

Follow Us

Help Us




Other Invest in ME Research Activity

Research

IIMER are facilitating a strategy of biomedical research into ME. The charity is currently funding possibly the two most important research projects for ME in the UK.
Currently the main hubs of research are at UEA/IFR in the Norwich Research Park and at UCL.

Advisory Board

The IIMER Advisory Board is made up of eminent reseachers who are helping the charity to form a credible and productive biomedical research strategy which will provide the best and qucikest route for possible treatments and curesfor this disease.

Research Funding

Invest in ME supports high quality, biomedical research into myalgic encephalomyelitis. We are open for applications for funding for such research and the charity welcomes applications for grants for projects of 6 months - 3 years duration.


Let's Do It For ME

Let's do it for ME! is a patient-driven campaign to raise awareness and vital funds for a UK centre of excellence for translational biomedical ME research, clinical assessment, diagnosis and treatment for patients, training and information for healthcare staff, based around the Norwich Research Park in the UK and aiming to work collaboratively with international biomedical researchers.

Research Colloquiums

In addition to the International ME Conference the charity also organises an annual International Research Colloquium which attracts researchers from around the world in order to discuss experiences and open up collaborations in order to find answers fir this disease.

Centre of Excellence for ME

Translational biomedical research - an iterative feedback of information between the basic and clinical research domains in order to accelerate knowledge translation from lab to bedside and back to lab again - allows translation of findings in basic research more quickly and efficiently into medical practice to produce more meaningful health outcomes and facilitate the sharing of repositories and research-based facilities and laboratories. This is the model IiME are attempting to promote in the proposal for an examination and research facility based in Norwich.